Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: Murine ortholog of the fletcher trait

Thrombosis and Haemostasis

Volumn 107, Issue 6, 2012, Pages 1141-1150

  Eileen Bird, J ^a   Smith, Patricia L ^a   Wang, Xinkang ^b   Schumacher, William A ^a   Barbera, Frank ^a   Revelli, Jean Pierre ^c   Seiffert, Dietmar ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b AGENNIX INC   (United States)

^c LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

Animal model; Gene knockout; Protease

Indexed keywords

HEPARIN; PLASMA KALLIKREIN;

ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING TIME; CAROTID ARTERY FLOW; CONTROLLED STUDY; FEMALE; HEMOSTASIS; KIDNEY HEMORRHAGE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOSIS; VEIN THROMBOSIS;

ANIMALS; BLEEDING TIME; CHLORIDES; DISEASE MODELS, ANIMAL; FERRIC COMPOUNDS; HEMORRHAGE; HEMOSTASIS; HETEROZYGOTE; MICE; MICE, KNOCKOUT; OLIGONUCLEOTIDES, ANTISENSE; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PLASMA KALLIKREIN; PREKALLIKREIN; THROMBOSIS; TIME FACTORS; VENOUS THROMBOSIS;

EID: 84861727362     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-10-0682     Document Type: Article

References (41)

1. Mandle RJ, Kaplan RP. Hageman factor substrates. J Biol Chem 1977; 252: 6097-6104.
2. Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood 2004; 103:4554-4561.
3. Hooley E, McEwan PA, Emsley J. Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zy-mogen activation. J Thromb Haemost 2007; 5: 2461-2466.
4. Schmaier AH. The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol 2003; 285: R1-R13.
5. Clermont A, Chilcote TJ, Kita T, et al. Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats. Diabetes 2011; 60: 1590-1598.
6. Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
7. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with haemostasis. J Exp Med 2006; 203: 513-518.
8. Pham M, Kleinschnitz C, Helluy X, et al. Enhanced cortical reperfusion protects coagulation factor XII-deficient mice from ischemic stroke as revealed by high-field MRI. NeuroImage 2010; 49: 2907-2914.
9. Renne T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012; 34: 31-41.
10. Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-5311.
11. Schmaier AH, Bradford H, Silver LD, et al. Hig h molecular weight kininogen is an inhibitor of platelet calpain. J Clin Invest 1986; 77: 1565-1573.
12. Puri RN, Zhou FX, Bradford H, et al. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain. Arch Biochem Bio-phys 1989; 271: 346-358.
13. Liu J, Gao B-B, Clermont AC, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nature Med 2011; 17: 206-211.
14. Motta G, Rojkjaer R, Hasan AA, et al. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 1998; 91: 516-528.
15. Schmaier AH. The plasma kallikrein-kinin system counterbalances the renin-an-giotensin system. J Clin Invest 2002; 109: 1007-1009.
16. Sealey JE, Atlas SA, Laragh JH. Linking the kallikrein and renin systems via activation of inactive renin. Am J Med 1978; 65: 994-1000.
17. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Int Med 2000; 45: 419-429.
18. Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasmi-nogen activator (tPA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522-525.
19. Hathaway W, Belhasen LP, Hathaway HS. Evidence for a new plasma thrombo-plastin factor. Blood 1965; 26: 521-532.
20. Wynne Jones D, Russell G, Allford SL, et al. Severe prekallikrein deficiency associated with homozygosity for an Arg94Stop nonsense mutation. Br J Hematol 2004; 127: 220-223.
21. Oram MP, Mumford AD, Morse C, et al. Management of anticoagulation for coronary artery bypass surgery in a patient with severe prekallikrein deficiency. J Car-diothoracic Vasc Anes 2006; 20: 580-582.
22. Harris MG, Exner T, Richard KA, et al. Multiple cerebral thrombosis in Fletcher factor (prekallikrein) deficiency: a case report. Am J Hematol 1985; 19: 387.
23. Currimbhoy Z, Vinciguerra V, Palakavongs P, et al. Fletcher factor deficiency and myocardial infarction. Am J Clin Pathol 1976; 65: 970.
24. Wang X, Smith PL, Hsu M-Y, et al. Deficiency in thrombin-activatable fibrinoly-sis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J Thromb Thrombolysis 2007; 23: 41-49.
25. Wang X, Cheng Q, Xu L, et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005; 3: 695-702.
26. Bird JE, Smith PL, Bostwick JS, et al. Bleeding response induced by anti-throm-botic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice. Thromb Res 2011; 127: 560-564.
27. Entes K, Laduca FM, Tourbaf KD. Fletcher factor deficiency, source of variations of the activated partial thromboplastin time test. Am J Clin Path 1981; 75: 626-628.
28. Qian Y, Pan J, Zhou X, et al. Molecular mechanism underlines heparin-induced thrombocytopenia and thrombosis. Prog Mol Biol Transl Sci. 2010; 93: 395-421.
29. Abdallah RT, Keum J-S, Lee M-H, et al. Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors. J Biol Chem 2010; 285: 35206-35215.
30. Merkulov S, Zhang WM, Komar AA, et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 2008; 111: 1274-1281.
31. Adams GN, Larusch GA, Stavrou E, et al. Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 2011; 117: 3929-3937.
32. White TA, Pan S, Witt TA, et al. Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor. Thromb Res 2010; 125: 84-89.
33. Tomasini-Johansson B, Mosher DF. Plasma fibronectin concentration in inbred mouse strains. Thromb Haemost 2009; 102: 1278-1280.
34. Wang X, Smith PL, Hsu M-Y, et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost 2006; 4: 1982-1988.
35. Chan JC, Ganopolsky JG, Cornelissen I, et al. The characterization of mice with a targeted combined deficiency of protein C and factor XI. Am J Pathol 2001; 158: 469-479.
36. Gruber A, Hanson SR. Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood 2003; 102: 953-955.
37. Gailani D, Renné T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost 2007; 5: 1106-1112.
38. Schumacher WA, Luettgen JM, Quan ML, et al. Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol 2010; 30: 388-392.
39. Lowenberg EC, Meijers JCM, Monia B P, et al. Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost 2010; 8: 2349-2357.
40. Zhang H, Löwenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010; 116: 4684-4692.
41. Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116: 695-702.